Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
|Articles|June 15, 2021
Process Development Improvements Post-Pandemic
Author(s)BioPharm International Editors
What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?
Advertisement
In this expert interview with BioPharm International, James Blackwell, president of The Windshire Group, LLC, explains key actions the biopharma can learn from its response to the COVID-19 pandemic that can be applied to improve process development for non-pandemic development programs.
Advertisement
Related to this article
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
AbbVie's c-Met ADC Temab-A showed a 15.6% response rate in late-line colorectal cancer ahead of its 2 new FDA breakthrough designations.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
Advertisement
Advertisement